Vimarsana
Biggest News Aggregation in the World

Page 6 - Safety Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safety Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safety Study Today - Breaking & Trending Today

Study Links Specific Drugs to Delusions of Parasitosis Risk - Vimarsana News

Study Links Specific Drugs to Delusions of Parasitosis Risk

Researchers conducted a case-control study of biometric and pharmaceutical data from 34 patients with delusions of parasitosis, which they compared to an age-matched control group of 53 women.

FDA approves topical treatment for junctional, dystrophic EB - Vimarsana News

FDA approves topical treatment for junctional, dystrophic EB

This is the first approved treatment for wounds associated with JEB and the second for patients with DEB, following the approval of a topical gene therapy in May 2023.

5 Best Collagen Supplements For Younger And Healthier Skin 2023 - Vimarsana News

5 Best Collagen Supplements For Younger And Healthier Skin 2023

The best collagen supplements can help keep your skin looking young and healthy. Find out the 5 best collagen supplements in 2023.

Myasthenia Gravis Treatment Landscape Rapidly Evolving - Vimarsana News

Myasthenia Gravis Treatment Landscape Rapidly Evolving

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.

Source: ajmc.com
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA) - Vimarsana News

FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

First head-to-head trial of biologics in EGPA, comparing a single monthly injection of FASENRA to three injections per month of mepolizumab ...